Related Experiment Videos
[Phase II clinical study of 99mTc-MAG3]
K Ishii1, A Ishibashi, E Tsukamoto
1Department of Radiology, Kitasato University, School of Medicine.
Kaku Igaku. the Japanese Journal of Nuclear Medicine
|April 1, 1993
Summary
Technetium (99mTc) mercaptoacetylglycyl-glycylglycinate (99mTc-MAG3) is a safe and effective radiopharmaceutical for diagnosing renal dynamic function. Optimal dosage ranges from 200-400 MBq, providing excellent image quality and clinical information.
Area of Science:
- Nuclear Medicine
- Radiopharmacology
- Nephrology
Background:
- Technetium (99mTc) mercaptoacetylglycyl-glycylglycinate (99mTc-MAG3) is a novel agent for scintigraphic and renographic imaging.
- Assessing the safety and efficacy of new diagnostic agents is crucial in clinical practice.
Purpose of the Study:
- To evaluate the safety, clinical usefulness, and optimal dosage of 99mTc-MAG3.
- To determine the diagnostic performance of 99mTc-MAG3 in patients with mild renal or urinary disorders.
Main Methods:
- A Phase II clinical study involving 88 patients across 5 institutions.
- Administration of 99mTc-MAG3 to assess safety, effectiveness, and image quality at varying dosages.
- Evaluation of adverse reactions and diagnostic information obtained.
Main Results:
- 99mTc-MAG3 demonstrated a favorable safety profile with no adverse reactions reported in any patient.
- The agent proved effective in all analyzed cases, yielding high-quality images and valuable clinical data.
- An optimal dosage range of 200-400 MBq was identified for effective renal dynamic function diagnosis.
Conclusions:
- 99mTc-MAG3 is a safe and clinically useful radiopharmaceutical for assessing renal dynamic function.
- The established dosage range ensures optimal diagnostic yield in patients with renal and urinary disorders.
- This agent represents a valuable tool for nuclear medicine and nephrology diagnostics.